Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies

News
Video

“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.

Primary care physicians and patients need to be aware of the long-term effects of various treatments, particularly involving chemotherapy, as it can lead to more substantial physical health declines.

Clara Bodelon, PhD, MS, senior principal scientist of survivor research at the American Cancer Society and lead study author of a paper published in JAMA Network Open that detailed the long-term physical health outcomes from various cancer treatments, told CancerNetwork® that the care for each respective patient must be individualized. If care is individualized, physicians will be better able to control who needs to get chemotherapy and who can be spared from it, thus avoiding long-term physical health declines.

She also spoke about potentially including physical therapy or other forms of care to relieve pain along with cancer treatment to help remedy or alleviate some of the longer-term physical health effects associated with treatments.

Transcript:

We are starting to try to think about personalized medicine and long-term outcomes—it’s going to be a consequence of that personalized medicine. Not all breast cancer survivors are the same and not all necessarily need the same care. We see that those taking chemotherapy are going to be the ones that are going to require the most help, and we need to understand if all chemotherapies are going to be the same, but [the care that these women receive] is going to have to be individualized.

The implication is that we need to inform patients, as well as primary care physicians, because someone could receive chemotherapy or a combination of chemotherapy with endocrine therapy, but if they have chemotherapy, it doesn’t matter if they have other treatments, they may suffer this decline. It may inform physicians that these women may need help long-term, going to physical therapy, for instance, and having it as part of their health care plan. They need these providers to help them offset some of the consequences of the treatment. That may not be the case for endocrine therapy. It may be that some women still need it, but because cancer care is expensive, we need to understand who the ones that need it the most are [and we need] to understand how we change treatments and what the consequences are. Our study starts shedding some light on that.

Reference

Bodelon C, Masters M, Bloodworth DE, et al. Physical health decline after chemotherapy or endocrine therapy in breast cancer survivors. JAMA Netw Open. 2025;8(2):e2462365. doi:10.1001/jamanetworkopen.2024.62365

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.